论文部分内容阅读
通过综合研究不同病期急性白血病、慢粒急变及骨髓增生异常综合征─-难治性贫血伴幼稚细胞增多（MDS－RAEB）患者外周血白血病细胞DNA、细胞周期及CD44的变化，发现其与临床的关系，以指导临床诊断及治疗。应用流式细胞仪（FCM）研究了46例急性白血病，10例慢粒急变及5例MDS－RAEB患者DNA指数、DNA倍体和S期百分率（SP）的分布及血液CD44表达情况，并与正常对照进行了比较。急性白血病、慢粒急变及MDS-RAEB三组患者DNA异倍体检出率相似；急性白血病难治／复发组DNA非整倍体率均高于完全缓解组，且FCM可发现体内存在的低于光镜检测水平的残留白血病细胞。初诊时呈现DNA整倍体及低DNA指数的急性白血病患者具有较好的治疗效果。患者组血液CD44表达与正常对照组间无显著性差异。急性白血病患者制定化疗方案时，DNA指数及DNA非整倍体率可作为一重要参考指标。
Through a comprehensive study on the changes of leukemia cell DNA, cell cycle, and CD44 in patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome--refractory anemia associated with increased number of immature cells (MDS-RAEB) in different stages of disease, it was found that Clinical relationships to guide clinical diagnosis and treatment. Flow cytometry (FCM) was used to study the distribution of DNA index, DNA ploidy and percentage of S phase (SP) and the expression of CD44 in 46 cases of acute leukemia, 10 cases of chronic granuloma, and 5 cases of MDS-RAEB. Normal controls were compared. The detection rate of DNA aneuploidy in patients with acute leukemia, CML and MDS-RAEB was similar. The aneuploidy rate of DNA in the refractory/relapsed group of acute leukemia was higher than that in the complete remission group, and FCM could be found to be lower in vivo. Light microscopic examination of residual leukemia cells. Patients with acute leukemia presenting with DNA euploid and low DNA index at the initial diagnosis have a good therapeutic effect. There was no significant difference in blood CD44 expression between the patient group and the normal control group. When an acute leukemia patient develops a chemotherapy regimen, DNA index and DNA aneuploidy rate can be used as an important reference.